Eagle Pharmaceuticals Interest Expense 2011-2026 | EGRX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Eagle Pharmaceuticals

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
4.04 M	1.64 M	2.58 M	2.69 M	2.74 M	1.14 M	8 K	11 K	8 K	309 K	91 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
4.04 M	8 K	1.39 M

Quarterly Interest Expense Eagle Pharmaceuticals

2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
1.45 M	1.52 M	-	1.15 M	552 K	366 K	-	396 K	422 K	422 K	-	489 K	786 K	889 K	-	628 K	665 K	686 K	-	743 K	701 K	675 K	-	527 K	40 K	27 K	-	3 K	3 K	-	-	5 K	3 K	1 K	1 K	2 K	5 K	1 K	-	309 K	16 K	145 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.52 M	1 K	426 K

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
AcelRx Pharmaceuticals ACRX	1.12 M	-	7.5 %	$ 6.35 M	USA
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
DURECT Corporation DRRX	2.24 M	-	-	$ 50.1 M	USA
Canopy Growth Corporation CGC	74.6 M	$ 1.11	4.27 %	$ 119 M	Canada
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Evoke Pharma EVOK	500 K	-	-	$ 36.6 M	USA
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Evolus EOLS	-539 K	$ 5.19	25.54 %	$ 335 M	USA
Avadel Pharmaceuticals plc AVDL	13 M	-	-	$ 2.06 B	France
Jupiter Wellness JUPW	-5.37 M	-	-	$ 33.6 M	USA
China Pharma Holdings CPHI	27.4 K	$ 0.58	2.89 %	$ 10.1 M	China
Cumberland Pharmaceuticals CPIX	606 K	$ 4.18	-8.73 %	$ 58.8 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
Harrow Health HROW	47 K	$ 39.81	3.11 %	$ 1.46 B	USA
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Emergent BioSolutions EBS	87.9 M	$ 8.69	-2.47 %	$ 445 M	USA
ProPhase Labs PRPH	764 K	-	-	$ 5.07 M	USA
Assertio Holdings ASRT	2.78 M	$ 12.24	2.9 %	$ 869 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
Bausch Health Companies BHC	-28 M	$ 5.63	-1.66 %	$ 2.05 B	Canada
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Organogenesis Holdings ORGO	20 K	$ 2.96	3.1 %	$ 390 M	USA
Rockwell Medical RMTI	2.3 M	$ 0.9	0.08 %	$ 21 M	USA
Perrigo Company plc PRGO	-13.2 M	$ 11.61	1.98 %	$ 1.61 B	USA
Sundial Growers SNDL	81 K	$ 1.55	1.31 %	$ 3.37 M	Canada
TherapeuticsMD TXMD	300 K	$ 2.24	0.94 %	$ 23.4 M	USA
Veru VERU	862 K	$ 2.67	5.95 %	$ 360 M	USA
Viatris VTRS	573 M	$ 14.7	-1.31 %	$ 17.6 B	USA
Pacira BioSciences PCRX	-373 K	$ 22.6	2.26 %	$ 1.05 B	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 4.77	2.14 %	$ 144 M	USA
cbdMD YCBD	-29.5 K	$ 0.8	3.77 %	$ 3.45 M	USA
SCYNEXIS SCYX	3.13 M	$ 0.77	2.75 %	$ 36.8 M	USA
Solid Biosciences SLDB	652 K	$ 6.15	3.19 %	$ 251 M	USA
Sonoma Pharmaceuticals SNOA	-10 K	$ 2.69	-2.18 %	$ 3.34 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
Tilray TLRY	46.6 M	$ 7.51	2.04 %	$ 4.64 B	Canada
Zynerba Pharmaceuticals ZYNE	80.2 K	-	-	$ 55.5 M	USA